BusinessCytovance Biologics, Inc. announces Bexion Pharmaceuticals Inc. has chosen Cytovance to manufacture the protein component and active ingredient of Bexion’s first clinical compound, BXQ-350By Nasdaq OMXNov 28, 2017, 10:00 AM UTC
